<DOC>
	<DOC>NCT00736320</DOC>
	<brief_summary>This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of Progression free survival (PFS).</brief_summary>
	<brief_title>HD16 for Early Stage Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Hodgkin Lymphoma CS I, II without risk factors large mediastinal mass (&gt; 1/3 of maximum transverse thorax diameter) extranodal involvement elevated ESR 3 or more involved nodal areas Written informed consent Leucocytes &lt; 3000/µl Platelets &lt; 100000/µl Hodgkin Lymphoma as composite lymphoma Activity index (WHO) &gt; 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>early stage</keyword>
	<keyword>PET</keyword>
</DOC>